The iShares Core S&P Total U.S. Stock Market ETF (ITOT) exhibits an implied analyst target price of $156.44, suggesting an 11.50% upside from its current $140.31 trading price, derived from the weighted average of its underlying holdings' 12-month forward analyst targets. Notable contributors to this projected upside include Lenz Therapeutics (LENZ), Amylyx Pharmaceuticals (AMLX), and Cidara Therapeutics (CDTX), with individual analyst target upsides of 26.66%, 26.50%, and 16.01% respectively. The analysis, however, also prompts investors to consider the justification and timeliness of these analyst targets.
Based on a weighted average of its underlying holdings' 12-month forward analyst targets, the iShares Core S&P Total U.S. Stock Market ETF (ITOT) has an implied target price of $156.44, representing an 11.50% upside from its recent price of $140.31. This potential is driven in part by specific holdings with significant analyst-projected appreciation. Notably, Lenz Therapeutics Inc (LENZ) and Amylyx Pharmaceuticals Inc (AMLX) exhibit potential upsides of 26.66% and 26.50% to their respective consensus targets. Similarly, Cidara Therapeutics Inc (CDTX) shows a 16.01% upside to its average target price of $74.00. While these figures indicate a moderately positive sentiment from analysts, the analysis itself questions whether these targets are justified or potentially outdated, highlighting that a high price target relative to a stock's current price requires further diligence to confirm its validity and to mitigate the risk of future target price downgrades.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
